Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
Authors
Keywords
-
Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 70, Issue -, Pages 49-55
Publisher
Elsevier BV
Online
2023-03-02
DOI
10.1016/j.euroneuro.2023.02.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression
- (2023) Giovanni Martinotti et al. BIPOLAR DISORDERS
- Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
- (2022) Ana Paula Jesus‐Nunes et al. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
- When depression is difficult to treat
- (2022) R.H. McAllister-Williams EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
- (2022) Anees Bahji et al. Expert Opinion On Drug Safety
- Rapid treatments for depression: Endocannabinoid system as a therapeutic target
- (2022) AmirMohammad Sharafi et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
- (2022) Stephen M. Stahl et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Arketamine, a new rapid-acting antidepressant: A historical review and future directions
- (2022) Ji-chun Zhang et al. NEUROPHARMACOLOGY
- Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)
- (2022) Giovanni Martinotti et al. JOURNAL OF AFFECTIVE DISORDERS
- Repeated subcutaneous esketamine for treatment-resistant depression: Impact of the degree of treatment resistance and anxiety comorbidity
- (2021) Ana C Lucchese et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
- (2021) Roger S. McIntyre et al. AMERICAN JOURNAL OF PSYCHIATRY
- The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL/6J mice
- (2021) Anna Rafało-Ulińska et al. BEHAVIOURAL BRAIN RESEARCH
- Glutamate modulators and beyond: A neuroscience revolution in the making
- (2021) Carlos A. Zarate EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials
- (2021) Luca Sforzini et al. MOLECULAR PSYCHIATRY
- The Effectiveness of Ketamine on Anxiety, Irritability, and Agitation: Implications for Treating Mixed Features in Adults with Major Depressive or Bipolar Disorder
- (2020) Roger S. McIntyre et al. BIPOLAR DISORDERS
- Mechanisms of action of currently used antiseizure drugs
- (2020) Graeme J. Sills et al. NEUROPHARMACOLOGY
- The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence
- (2020) Roger S McIntyre et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine
- (2019) Lijia Chang et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Bipolar depression: the clinical characteristics and unmet needs of a complex disorder
- (2019) Roger S. McIntyre et al. CURRENT MEDICAL RESEARCH AND OPINION
- Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study
- (2018) Lorenzo Mazzarini et al. JOURNAL OF AFFECTIVE DISORDERS
- Role of NMDA receptor GluN2D subunit in the antidepressant effects of enantiomers of ketamine
- (2017) Soichiro Ide et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature
- (2016) J.F. Costemale-Lacoste et al. ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE
- HCN-channel dendritic targeting requires bipartite interaction with TRIP8b and regulates antidepressant-like behavioral effects
- (2016) Y Han et al. MOLECULAR PSYCHIATRY
- Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors
- (2016) Priscila B. Rosa et al. Pharmacological Reports
- The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project
- (2015) Roger S. McIntyre et al. JOURNAL OF AFFECTIVE DISORDERS
- The Bipolarity index: a clinician-rated measure of diagnostic confidence
- (2015) Chris B. Aiken et al. JOURNAL OF AFFECTIVE DISORDERS
- Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
- (2010) Christina L. Nemeth et al. PSYCHOPHARMACOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More